Clinical trial
Cirrhotic Ascites Treatment With Satavaptan in Patients With Ascites Due to…
NCT00358878 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00358878 |
|---|---|
| Title | Cirrhotic Ascites Treatment With Satavaptan in Patients With Ascites Due to Cirrhosis of the Liver (CATS) |
| Official title | Satavaptan Cirrhotic Ascites Treatment Study: a Double-blind, Randomised, Parallel-group Comparison of Treatment With Satavaptan at 5 to 10 mg Daily Versus Placebo on Top of Conventional Treatment in Patients With Ascites Due to Cirrhosis of the Liver |
| Acronym | CATS |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Ascites, Liver Cirrhosis |
| Intervention type | Drug |
| Interventions | Satavaptan, placebo |
| Enrollment | 463 |
| Start date | Jul 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Aug 1, 2006 |
| Last update posted | May 26, 2016 |
| Countries | Argentina, Australia, Belgium, Brazil, Canada, Chile, Croatia, Denmark, France, Hungary, Israel, Italy and 9 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: